Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Paediatrics and Oncology

Journal homepage: <https://www.ijmpo.com/>

Original Research Article

Clinicopathological profile of female genital tract malignancies reported at a tertiary care center in Northern India

Syed Fiza Mustaqueem^{1,*}, Syed Belal Hassan², Syed Shamshad Ahmad³¹Dept. of Pathology, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh, India²Dept. of Community Medicine, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh, India³Dept. of Pathology, Jawaharlal Nehru Medical College, Aligarh, Uttar Pradesh, India

ARTICLE INFO

Article history:

Received 01-06-2021

Accepted 24-06-2021

Available online 03-08-2021

Keywords:

Female genital tract malignancies

Morbidity

Histological subtypes

Northern India

ABSTRACT

Background : The proportion of cancers of genital tract origin in females ranges from 22.4% to 55.8% in India; thus posing a major health problem. The first step in controlling the cancer burden in any population is to collect information about its salient features in that particular cohort of patients. This study was performed to ascertain the profile of female genital tract malignancies reported at our center regarding the relative frequency of involvement of various sites, age and symptoms at presentation and histological subtypes.

Materials and Methods: All the confirmed cases of female genital tract malignancies received in the Department of Pathology were studied for a period of 2 years from November 2008 to October 2010.

Result: A total of 175 cases were reported. The anatomic distributions were: cervix 123 (70.3%), uterus 11 (6.3%), ovary 30 (17.1%), vagina 4 (2.3%), vulva 5 (2.9%) and fallopian tube 2 (1.1%). The mean ages of women diagnosed with these cancers were: cervix (51.1 years), uterus (54.5 years), ovary (46.5 years), vagina (57 years), vulva (54.5 years) and fallopian tube (49.5 years). Women with cervical and uterine malignancies presented commonly with bleeding per vaginum; while those with ovarian malignancies presented mostly with abdominal mass. Women with vaginal and vulval malignancy presented with ulcers and masses. The most common histological subtypes at different sites were: Cervix: Squamous cell carcinoma (SCC) (87%); Uterus: Endometrioid adenocarcinoma (81.8%); Ovary: Serous cystadenocarcinoma (53.3%); Vagina: SCC (75%); Vulva: SCC (60%) and Fallopian tube (50% adenocarcinoma and 50 % metastatic carcinoma).

Conclusion : As female genital tract malignancies form a huge burden of morbidity and mortality in India, there is a need to establish better screening programmes aimed at early detection and educate the public regarding the risk factors as well as early symptoms of the disease so that people can adapt appropriate behaviour.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Female genital tract (FGT) is the site of large number of tumours of considerable diversity, some very common and some extremely uncommon. However due to lack of cancer awareness and effective screening programmes in most developing countries including India, these malignancies constitute a major health burden.^{1,2} Also

these tumours have dissimilar pattern of distribution and clinical presentation worldwide with ethnic, environmental and geographic variation. However the data relating to the clinicopathological characteristics of these tumours is deficient from Indian subcontinent indicating significant knowledge gap. An attempt is therefore made in the present study to assess the relative proportions and clinicopathological characteristics of FGT malignancies in our institution by a descriptive prospective histopathological study.

* Corresponding author.

E-mail address: syedfizam@gmail.com (S. F. Mustaqueem).

2. Materials and Methods

All cases reported at our center or referred to it and treated in the Department of Gynaecology over a period of 2 years were reviewed. The clinical data was collected from patient record files, discharge books and pathology request forms. From these data sources, age at diagnosis, clinical presentation at diagnosis, part of FGT affected and histopathological characteristics were extracted. The data were entered into a computerized spreadsheet and analysis performed using Advanced Excel Sheet. Frequency distributions and descriptive statistics were calculated for each variable.

3. Results

3.1. Spectrum of FGT malignancies

A total of 175 cases of FGT malignancies were reported during the period under study. The anatomical distribution of these malignancies were: Cervix 123 (70.3%), Ovary 30 (17.1%), Uterus 11 (6.3%), Vagina 4 (2.3%), Vulva 5 (2.9%) and Fallopian tube 2 (1.1%). Thus, cervix was the most common and fallopian tube the least common site of FGT malignancy in our study (Table 1).

Fig. 1: Distribution of cases of FGT malignancy according to site

Table 1: Distribution of cases of FGT malignancy according to site

Site of tumour	No. of cases	Percentage
Cervix	123	70.3
Ovary	30	17.1
Uterus	11	6.3
Vagina	4	2.3
Vulva	5	2.9
Fallopian tube	2	1.1
Total	175	100

3.2. Age distribution of various subtypes of FGT malignancies

The ages of 175 women with FGT malignancies ranged from 10-69 years with a mean of 50.7 years. Majority of FGT malignancies (35.4%) were seen in the sixth decade, followed by 27 % cases in fifth decade and 23.4% cases in the seventh decade onwards. It was noted that the FGT malignancies were rare before the age of 20 years (Table 2).

Fig. 2: Distribution of cases of FGT malignancies according to different age groups

Table 2: Distribution of cases of FGT malignancies according to different age groups

Age group (years)	No. of malignant cases	Percentage
<20	2	1.1
20-29	6	3.4
30-39	17	9.7
40-49	47	27
50-59	62	35.4
≥60	41	23.4
Total	175	100

The ages of 123 women with malignancies of cervix ranged from 28-69 years with maximum number of cases 44(35.7%) in the age group of 50-59 years and a mean age of 51.1 years. The ages of 30 women with ovarian malignancies ranged from 18-65 years with maximum number of cases in the age group of 40-49 years and a mean age of 46.5 years. The ages of 11 women with malignancies of uterus ranged from 37-68 years with maximum number of cases 5(45%) in the age group of 60-69 years and a mean age of 54.5 years. The ages of 4 women with malignancy of vagina ranged from 55-67 years with maximum cases 3(75%) in the age group of 50-59 and a mean age of 57 years. The age of 5 women with vulval malignancy ranged from 48-68 years with maximum number of cases 3(60%) in the age group of 50-59 years and a mean age of 54.5 years.

Table 3: Age wise distribution of individual malignant tumours of FGT

Age group (years)	Cervix	Ovary	Uterus	Vagina	Vulva	Fallopian tube
<20	0	2	0	0	0	0
20-29	3	3	0	0	0	0
30-39	13	2	2	0	0	0
40-49	35	9	1	0	1	1
50-59	44	8	3	3	3	1
≥60	28	6	5	1	1	0
Total	123	30	11	4	5	2

The age of 2 women with fallopian tube malignancy ranged from 47-56 years with 1 case each in the age group of 40-49 years and 50-59 years (Table 3).

3.3. Symptoms at presentation of FGT malignancies

Females with malignancies of cervix and endometrium commonly presented with bleeding per vaginum in 70 (56.9%) and 9 (81.8%) cases respectively. Females with ovarian malignancies commonly presented with abdominal mass in 15 (50%); vulval and vaginal malignancies with ulcer/mass 2(50%) and 3 (60%) respectively. 1 case of fallopian tube malignancy presented with abdominal mass and the other case was detected incidentally (Table 4).

3.4. Histological subtypes of FGT malignancies

The most common histological variant of malignancy at different sites were; Cervix - Squamous cell carcinoma (SCC) 87%, Ovary – Serous cystadenocarcinoma (53.3%), Uterus - Endometrioid carcinoma (81.8%), Vagina – SCC (75%) and Vulva – SCC (60%). 1 case each of adenocarcinoma and metastatic carcinoma were reported in fallopian tube (Table 5).

4. Discussion

During the period of 2 years under study, a total of 175 cases of FGT malignancies were diagnosed in our institution; out of which majority were from cervix (70.3%), followed by ovary (17.1%), uterus (6.3%), vulva (2.9%), vagina (2.3%) and fallopian tube (1.1%). This supports previous institutional based studies from other developing countries that found the commonest FGT malignancy to be cancer of uterine cervix.³⁻⁸ However the pattern of malignancy in our study differs from a study by Momtahn in Iran that showed a higher incidence of endometrial cancer (58%) and lesser prevalence of cervical cancer (13.6%).⁹ The prevalence of cervical cancer in the current study, like in other developing countries has been attributed to the high prevalence of child marriage, early sexual activity, ignorance and lack of effective cancer screening programmes.

The mean age of women diagnosed with cancer of cervix was 51.9 years and maximum cases were in the age group of 50-59 years. However the data from Surveillance,

Epidemiology and End Results Program of United States and European Union showed significantly higher proportion of cervical malignancies in the younger age group as compared to those reported at our center.¹⁰ This may be a manifestation of better screening programmes in the US where cervical malignancy is detected in younger patients at a localized stage.

In the current study, the most common clinical presentation of women with carcinoma cervix was bleeding per vaginum; similar to other previous studies.^{11,12}

The most common histological subtype of cervical cancer was SCC (87%), followed by adenocarcinoma (8.2%) and adenosquamous carcinoma (1.6%). This was in concordance with the study of Shingleton et al¹³ who has reported 83.8% cases of cervical carcinoma as SCC, 12.6 % as adenocarcinoma and 3.6% as adenosquamous carcinoma.

Ovary was the second leading site among FGT malignancies at our centre; constituting 17.1% of total FGT malignancies. This is in accordance with the data from Globocon 2002 which also shows a relatively higher incidence of ovarian malignancies in the West; similar to data from NCRP and other cancer registries in India.¹⁴⁻¹⁶

Most of the cases of ovarian malignancy occurred in the fifth decade and the mean age was 46.5 years. Yeole et al¹⁷ have also reported maximum number of ovarian malignancies in the age group of 45-55 years.

The most common presenting complaint in cases of ovarian malignancy was lump in abdomen (80%), followed by pain in abdomen (73.3%). This corresponded with the findings of Maheshwari et al¹⁸ who also found abdominal lump as presenting feature in 71.9% cases, followed by pain in abdomen in 47.4% cases.

Serous cystadenocarcinoma was the commonest malignant tumour of ovary in this study which accounted for 53.3% of malignant ovarian tumours. Katzenstein et al¹⁹ found that that borderline and invasive tumours together constituted 35-40% of all malignant ovarian tumours.

In our study, carcinoma of uterine corpus was the third most common site of malignancy constituting 6.3% of all FGT malignancies. Jamal et al²⁰ also reported uterine malignancy to be the third most common amongst the gynaecological malignancies with an incidence of 16%.

Endometrial cancer is the cancer of post-menopausal females. The study showed maximum cases of endometrial

Table 4: Symptoms at presentation of malignancy of FGT

Symptoms	Cervix	Endometrium	Ovary	Vagina	Vulva	Fallopian tube
Bleeding per vaginum	70	9	4	1	2	0
Vaginal discharge	22	0	0	0	0	0
Ulcer/mass	15	0	0	2	3	0
Abdominal mass	0	0	15	0	0	1
Abdominal pain	0	0	7	0	0	0
Menorrhagia	4	2	2	0	0	0
Others	2	0	2	1	0	1

Table 5: Distribution of FGT malignancies according to histological type

Site	Histological type	No. of cases	Percentage
Cervix	Squamous cell carcinoma	107	87
	Adenocarcinoma	11	8.9
	Adenosquamous carcinoma	2	1.6
	Metastatic carcinoma	3	2.4
	Endometrioid adenocarcinoma	9	81.8
Uterus	Leiomyosarcoma	1	9.1
	Choriocarcinoma	1	9.1
Ovary	Serous cystadenocarcinoma	16	53.3
	Mucinous cystadenocarcinoma	6	20
	Dysgerminoma	2	6.7
	Yolk sac tumour	1	3.3
	Immature teratoma	2	6.7
	Granulosa cell tumour	1	3.3
	Metastatic carcinoma	2	6.7
	Squamous cell carcinoma	3	75
Vagina	Adenocarcinoma	1	25
	Squamous cell carcinoma	3	60
Vulva	Metastatic carcinoma	2	40
	Adenocarcinoma	1	50
Fallopian tube	Adenocarcinoma	1	50
	Metastatic	1	50

carcinoma in the sixth decade and the mean age was 54.5 years. This was consistent with the findings of Jamal et al²⁰ who has reported the mean age of patients with endometrial carcinoma as 52.5 years.

The most common complaint of the patients of endometrial carcinoma in this study was abnormal uterine bleeding which was observed in 81.8% cases. Similar findings were reported by Hacker et al.²¹

Amongst the various histological subtypes of uterine malignancy, endometrioid adenocarcinoma was the most frequent type constituting 82% of all cases. Similar findings were observed by Platz et al²² who reported it to be 81.5%.

Vagina, vulva and fallopian tubes were the less common sites of malignancy when compared to other sites of FGT. In the current study, the proportion of malignancy in these sites were reported to be 2.3%, 2.9% and 1.1% respectively of the total FGT malignancies. This finding suggests that cancer of vulva and vagina are not rare malignancies as determined in some studies.^{23,24} In the current study, fallopian tube (1.1%) was the least common site of malignancy in FGT. This differs from a study in Nigeria which reported vagina to be the least prevalent cancer of the FGT.²⁵

The cases of vaginal, vulval and fallopian tube malignancy were reported in the fifth decade onwards. The mean age of diagnosis in vagina was 57 years, vulva 54.5 years and fallopian tube 49.5 years. This was in accordance with the findings of Jamal et al²⁰ who has reported these cases in the age group of 40-60 years.

Women with vaginal cancer and vulval cancer presented with ulcers and mass, similar to other studies. This differs from a study on vaginal cancer that reported bleeding per vaginum as the most frequent mode of presentation.²⁶

In our study, squamous cell carcinoma constituted 60% cases of vulval and 75% cases of vaginal malignancy. This was in accordance with the findings of Platz et al²² who also reported SCC to be the most common malignancy of vulva and vagina constituting 74.4% and 70.8% respectively.

In our study, 25% cases of vaginal malignancy were clear cell adenocarcinoma. Beller et al²⁷ have reported vaginal adenocarcinoma in 14% cases.

Both the cases of fallopian tube malignancy in this study were serous adenocarcinoma, one primary and the other metastatic. Baekelandt et al²⁸ have also reported serous adenocarcinoma as the most common malignancy of

fallopian tube.

5. Conclusion

Although cancers of FGT are an important cause of morbidity and mortality among women worldwide; but there is significant lacunae in the FGT cancer detection programmes in India. So larger and more detailed study on the trends of FGT cancers is essential to plan better cancer detection strategies for specific age groups at risk.

6. Conflict of Interest

The authors declare that there are no conflicts of interest in this paper.

7. Source of Funding

None.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C. Estimates of worldwide burden of cancer in 2008: GLOBOCON. *Int J Cancer*. 2008;127:2893–917.
2. World Health Organization. World Cancer Report 2008. Lyon: International Agency for Research on Cancer ; 2008.
3. Basile S, Angioli R, Mancini N, Palaia I, Plotti F. Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting. *Int J Gynecol Cancer*. 2006;16:1491–7.
4. Mishra K. Gynecological malignancies from palliative care perspective. *Indian J Palliat Care*. 2011;17:45–51.
5. Hanoon PP, Nibedita B, Dhruba U. Malignancies of the female genital tract. *J Obstet Gynaecol Cancer*. 2007;2:35–8.
6. Khursheed F, Jatoti N, Das CM. Genital tract malignancies in post menopausal women. *J Ayub Med Coll Abbottabad*. 2010;22:32–4.
7. Mishra K. Gynaecological malignancies from palliative care perspective. *Indian J Palliat Care*. 2011;17:45–51.
8. Nkyekyer K. Pattern of gynaecological cancers in Ghana. *East Afr Med J*. 2000;77:534–8.
9. Momtahn S, Kadivar M, Kazzazi AS, Gholipur F. Assessment of gynaecologic malignancies: a multi-center study in Tehran. *Indian J Cancer*. 1995;46:226–30.
10. Bethesda M. Seer.cancer.gov. Bethesda, Maryland: North American Association of Central Cancer Registries; c2000. SEER Cancer statistics review; 1975-2007.
11. Hamad HM. Cancer initiatives in Sudan. *Ann Oncol*. 2006;17:32–6.
12. Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology . In: 8th Edn.. vol. 8. Saunders Elsevier; 2007. p. 718–21.
13. Shingleton HM, Bell MC, Fremgen A, Chmiel JS, Russell AH, Jones WB, et al. There really a difference in survival of women with squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma of the cervix? *Cancer*. 1995;76:1948–55.
14. Indian Council of Medical Research. Bangalore: National Cancer Registry Programme-2007. Consolidated Report of Hospital Based Cancer Registries; 2001-2003.
15. Chhabra S, Sonak M, Prem V, Sharma S. Gynaecological malignancies in a rural institute in India. *J Obstet Gynaecol*. 2002;22:426–9.
16. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCON 2002: Cancer Incidence, Mortality and prevalence Worldwide. IARC Press; 2004.
17. Yeole BB, Kumar AV, Kurkure A, Sunny L. Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India. *Asian Pac J Cancer Prev*. 2004;5:308–15.
18. Maheshwari V, Tyagi SP, Saxena K, Tyagi N, Sharma R, Aziz M, et al. surface epithelial tumours of ovary. *Indian J Pathol Microbiol*. 1994;37:75–85.
19. Katzenstein AI, Mazur MT, Morgan TE, Kao MS. Proliferative serous tumours of ovary: Histologic features and prognosis. *Am J Surg Pathol*. 1978;2:339–55.
20. Jamal S, Mamoon N, Mushtaq S, Luqman M, Moghal S. The pattern of gynaecological malignancies in 968 cases from Pakistan. *Ann Saudi Med*. 2006;26:382–4.
21. Hacker NF. Practical Gynaecologic Oncology. In: 3rd Edn. Philadelphia: Lippincott, William and Wilkins; 2000. p. 407–55.
22. Ce P, Benda JA. Female genital tract cancer. *Cancer*. 1995;75:270–94.
23. Anderson ES, Paavonen J, Murnaghan M. WHO Classification of Tumours No 4. Pathology and Genetics Tumours of the Breast and Female Genital Organs. Lyon, France; 2003. p. 291–311.
24. Cancer Facts and Figures for 2009. American Cancer Society; 2009.
25. Ugwu EO, Ifeikigwe ES, Okeke TC, Ugwu AO, Okezie OA, Agu PU, et al. Pattern of gynaecological cancers in University of Nigeria Teaching Hospital. *Niger J Med*. 2011;20(2):266–9.
26. Vaginal Cancer. Gynaecologic malignancies 2005. Armenian Health Network, Health am.
27. Beller U. Carcinoma of the vagina. *Int J Gynaecol Obstet*. 2003;83:27–39.
28. Baekelandt M, Jorunn MA, Kristensen GB, Trope CG, Abeler VM. Carcinoma of the fallopian tube. *Cancer*. 2000;89(10):2076–84.

Author biography

Syed Fiza Mustaqueem, Assistant Professor

Syed Belal Hassan, Assistant Professor

Syed Shamshad Ahmad, Professor

Cite this article: Mustaqueem SF, Hassan SB, Ahmad SS. Clinicopathological profile of female genital tract malignancies reported at a tertiary care center in Northern India. *IP Int J Med Paediatr Oncol* 2021;7(2):85-89.